Navigating the gene & cell therapy regulatory landscape: when, why and how to deploy GMP gene editing materials

Watch the video or view the poster to learn more about: When and why you should transition from RUO to cGMP gene editing materials for gene & cell therapy development Why phase-appropriate gene editing materials (sgRNA, Cas9, DNA insert templates) are key in supporting gene & cell therapy development How to avoid long production delays with cGMP materials

Please enter your email to access content Read now